Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 227

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Leiter, Lawrence A., Yoon, Kun-Ho, Arias, Pablo, Langslet, Gisle, Xie, John, Balis, Dainius A., Millington, Dawn, Vercruysse, Frank, Canovatchel, William, Meininger, Gary·2015·Diabetes Care

Abstract

OBJECTIVE: To assess the efficacy/safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, compared with glimepiride over 104 weeks in patients with type 2 diabetes inadequately controlled with metformin. RESEARCH DESIGN AND METHODS: In this randomized, double-blind study, patients (N = 1,450) received canagliflozin 100 or 300 mg or glimepiride (titrated up to 6 or 8 mg/day) during a 52-week core period followed by a 52-week extension. RESULTS: At week 104, reductions from baseline in A1C were −0.65%, −0.74%, and −0.55% (−7.1, −8.1, and −6.0 mmol/mol) with canagliflozin 100 and 300 mg and glimepiride, respectively. Durability analyses showed sustained A1C lowering with both canagliflozin doses versus glimepiride. Reductions in body weight (−4.1%, −4.2%, and 0.9%, respectively) and systolic blood pressure (−2.0, −3.1, and 1.7 mmHg, respectively) were seen with canagliflozin 100 and 300 mg compared with glimepiride at week 104. The overall adverse event (AE) incidence was 73.3%, 77.9%, and 78.4% with canagliflozin 100 and 300 mg and glimepiride; the incidence of AE-related discontinuations was low across groups (6.2%, 9.5%, and 7.3%, respectively). Incidences of genital mycotic infections, urinary tract infections, and osmotic diuresis–related AEs were higher with canagliflozin than glimepiride; these were generally mild to moderate in intensity and led to few discontinuations. Fewer patients had hypoglycemia episodes with canagliflozin 100 and 300 mg than glimepiride (6.8%, 8.2%, and 40.9%). Mild decreases in estimated glomerular filtration rate occurred initially with canagliflozin; these attenuated over 104 weeks. CONCLUSIONS: Canagliflozin provided durable glycemic improvements compared with glimepiride and was generally well tolerated in patients with type 2 diabetes receiving background treatment with metformin over 104 weeks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc13-2762

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 24

  1. Bays, 2008, Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity, Expert Rev Cardiovasc Ther, 6, 343, 10.1586/14779072.6.3.343 · DOI · Paper page
  2. Cook, 2007, Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care, Diabet Med, 24, 350, 10.1111/j.1464-5491.2007.02078.x · DOI · Paper page
  3. Brown, 2010, Secondary failure of metformin monotherapy in clinical practice, Diabetes Care, 33, 501, 10.2337/dc09-1749 · DOI · Paper page
  4. Bennett, 2011, Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations, Ann Intern Med, 154, 602, 10.7326/0003-4819-154-9-201105030-00336 · DOI · Paper page
  5. Neumiller, 2010, Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus, Drugs, 70, 377, 10.2165/11318680-000000000-00000 · DOI
  6. Abdul-Ghani, 2011, Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes, Endocr Rev, 32, 515, 10.1210/er.2010-0029 · DOI · Paper page
  7. Chao, 2010, SGLT2 inhibition—a novel strategy for diabetes treatment, Nat Rev Drug Discov, 9, 551, 10.1038/nrd3180 · DOI · Paper page
  8. Bode, 2013, Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial, Hosp Pract (1995), 41, 72, 10.3810/hp.2013.04.1020 · DOI · Paper page
  9. Cefalu, 2013, Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial, Lancet, 382, 941, 10.1016/S0140-6736(13)60683-2 · DOI · Paper page
  10. Rosenstock, 2012, Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes, Diabetes Care, 35, 1232, 10.2337/dc11-1926 · DOI · Paper page
  11. Schernthaner, 2013, Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial, Diabetes Care, 36, 2508, 10.2337/dc12-2491 · DOI · Paper page
  12. Stenlöf, 2013, Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise, Diabetes Obes Metab, 15, 372, 10.1111/dom.12054 · DOI · Paper page
  13. Yale, 2013, Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease, Diabetes Obes Metab, 15, 463, 10.1111/dom.12090 · DOI · Paper page
  14. Lavalle-González, 2013, Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial, Diabetologia, 56, 2582, 10.1007/s00125-013-3039-1 · DOI · Paper page
  15. Wilding, 2013, Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial, Int J Clin Pract, 67, 1267, 10.1111/ijcp.12322 · DOI · Paper page
  16. Gallwitz, 2012, 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial, Lancet, 380, 475, 10.1016/S0140-6736(12)60691-6 · DOI · Paper page
  17. Matthews, 2010, Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study, Diabetes Obes Metab, 12, 780, 10.1111/j.1463-1326.2010.01233.x · DOI · Paper page
  18. Jendle, 2009, Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue, Diabetes Obes Metab, 11, 1163, 10.1111/j.1463-1326.2009.01158.x · DOI · Paper page
  19. Neal, 2013, Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—a randomized placebo-controlled trial, Am Heart J, 166, 217, 10.1016/j.ahj.2013.05.007 · DOI · Paper page
  20. Johnsson, 2013, Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin, J Diabetes Complications, 27, 479, 10.1016/j.jdiacomp.2013.04.012 · DOI · Paper page
  21. Johnsson, 2013, Urinary tract infections in patients with diabetes treated with dapagliflozin, J Diabetes Complications, 27, 473, 10.1016/j.jdiacomp.2013.05.004 · DOI · Paper page
  22. Rosenstock, 2013, Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia, Diabetes Obes Metab, 15, 1154, 10.1111/dom.12185 · DOI · Paper page
  23. Devineni, 2012, Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin, Diabetes Obes Metab, 14, 539, 10.1111/j.1463-1326.2012.01558.x · DOI · Paper page
  24. Williams-Herman, 2008, Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis, BMC Endocr Disord, 8, 14, 10.1186/1472-6823-8-14 · DOI

Cited by

See all 227

Metadata

Authors
Leiter, L. A., Yoon, K.-H., Arias, P., Langslet, G., Xie, J., Balis, D. A., Millington, D., Vercruysse, F., Canovatchel, W., & Meininger, G.
Venue
Diabetes Care
Published
2014-09-09
Volume
38
Issue
3
Pages
355-364
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2166823746
Cited by
227
References
6
FWCI
27.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. https://app.cochat.ai/papers/10.2337/dc13-2762
The paper
Leiter, L. A., Yoon, K.-H., Arias, P., Langslet, G., Xie, J., Balis, D. A., Millington, D., Vercruysse, F., Canovatchel, W., & Meininger, G. (2015). Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. Diabetes Care. https://doi.org/10.2337/dc13-2762

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.